PE20140872A1 - Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple - Google Patents
Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multipleInfo
- Publication number
- PE20140872A1 PE20140872A1 PE2013001357A PE2013001357A PE20140872A1 PE 20140872 A1 PE20140872 A1 PE 20140872A1 PE 2013001357 A PE2013001357 A PE 2013001357A PE 2013001357 A PE2013001357 A PE 2013001357A PE 20140872 A1 PE20140872 A1 PE 20140872A1
- Authority
- PE
- Peru
- Prior art keywords
- laquinimod
- improve
- patients
- life
- multiple sclerosis
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO QUE COMPRENDE ADMINISTRAR ORALMENTE LAQUINIMOD O UNA SAL DEL MISMO A UN PACIENTE HUMANO CON ESCLEROSIS MULTIPLE RECURRENTE-REMITENTE, PARA REDUCIR O INHIBIR LA PROGRESION DEL NIVEL DE FATIGA, PARA MEJORAR O INHIBIR EL DETERIORO DEL ESTADO FUNCIONAL, PARA MEJORAR O INHIBIR EL DETERIORO DE LA SALUD GENERAL. EL LAQUINIMOD SE ADMINISTRA EN UNA DOSIS DIARIA DE 0.3-0.9 mg, EN UN PERIODO MAYOR A 24 SEMANAS. SE REFIERE TAMBIEN A UN METODO PARA PROPORCIONAR NEUROPROTECCION A UN SUJETO HUMANO ADMINISTRANDOLE ORALMENTE LAQUINIMOD O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42074210P | 2010-12-07 | 2010-12-07 | |
| US201161542996P | 2011-10-04 | 2011-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140872A1 true PE20140872A1 (es) | 2014-08-09 |
Family
ID=46162796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001357A PE20140872A1 (es) | 2010-12-07 | 2011-12-06 | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20120142730A1 (es) |
| EP (1) | EP2648732A4 (es) |
| JP (2) | JP2013544887A (es) |
| KR (1) | KR20130124518A (es) |
| CN (1) | CN103260624B (es) |
| AU (2) | AU2011338647A1 (es) |
| BR (1) | BR112013014061A2 (es) |
| CA (1) | CA2820586A1 (es) |
| CL (1) | CL2013001602A1 (es) |
| EA (1) | EA201390827A1 (es) |
| IL (1) | IL250726A0 (es) |
| MX (1) | MX2013006464A (es) |
| NZ (1) | NZ611628A (es) |
| PE (1) | PE20140872A1 (es) |
| PH (1) | PH12013501193A1 (es) |
| SG (2) | SG10201509831XA (es) |
| UA (1) | UA111959C2 (es) |
| WO (1) | WO2012078591A1 (es) |
| ZA (1) | ZA201304237B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1937642E (pt) * | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| PL2234485T3 (pl) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stabilne preparaty lakwinimodu |
| KR20160148050A (ko) * | 2009-07-30 | 2016-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 크론병의 치료 |
| US9585878B2 (en) | 2009-08-10 | 2017-03-07 | Teva Pharmaceutical Industries, Ltd. | Treatment of BDNF-related disorders using laquinimod |
| PH12012501740A1 (en) * | 2010-03-03 | 2012-11-12 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| KR20160129093A (ko) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| WO2012006538A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| AU2013323131A1 (en) * | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| JP2015533163A (ja) * | 2012-10-12 | 2015-11-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症における視床損傷を低減するためのラキニモド |
| US8975279B2 (en) | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
| CA2900503A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| CA2900977A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
| US20150174118A1 (en) * | 2013-12-20 | 2015-06-25 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod to delay huntington's disease progression |
| HK1225969A1 (zh) * | 2014-01-17 | 2017-09-22 | Teva Pharmaceutical Industries Ltd | 利用低剂量的拉喹莫德治疗克隆氏病 |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| MX2017004808A (es) * | 2014-10-16 | 2017-07-26 | Novartis Ag | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| CN112770748A (zh) * | 2018-10-09 | 2021-05-07 | 美迪诺亚公司 | 异丁司特和干扰素-β的组合及其使用方法 |
| BR112022001138A2 (pt) * | 2019-07-22 | 2022-03-15 | Actelion Pharmaceuticals Ltd | Métodos de tratamento de esclerose múltipla |
| CN110688373A (zh) * | 2019-09-17 | 2020-01-14 | 杭州绿度信息技术有限公司 | 一种基于逻辑回归的offset方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR20140091778A (ko) * | 2006-06-12 | 2014-07-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| EP2680010A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| SI2442651T1 (sl) * | 2009-06-19 | 2015-10-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje multiple skleroze z lakvinimodom |
-
2011
- 2011-12-06 SG SG10201509831XA patent/SG10201509831XA/en unknown
- 2011-12-06 UA UAA201308448A patent/UA111959C2/uk unknown
- 2011-12-06 MX MX2013006464A patent/MX2013006464A/es unknown
- 2011-12-06 WO PCT/US2011/063460 patent/WO2012078591A1/en not_active Ceased
- 2011-12-06 EP EP11846599.6A patent/EP2648732A4/en not_active Withdrawn
- 2011-12-06 PE PE2013001357A patent/PE20140872A1/es not_active Application Discontinuation
- 2011-12-06 BR BR112013014061A patent/BR112013014061A2/pt not_active Application Discontinuation
- 2011-12-06 EA EA201390827A patent/EA201390827A1/ru unknown
- 2011-12-06 CN CN201180060414.8A patent/CN103260624B/zh not_active Expired - Fee Related
- 2011-12-06 SG SG2013042403A patent/SG190449A1/en unknown
- 2011-12-06 NZ NZ611628A patent/NZ611628A/en not_active IP Right Cessation
- 2011-12-06 US US13/312,284 patent/US20120142730A1/en not_active Abandoned
- 2011-12-06 JP JP2013543255A patent/JP2013544887A/ja active Pending
- 2011-12-06 PH PH1/2013/501193A patent/PH12013501193A1/en unknown
- 2011-12-06 AU AU2011338647A patent/AU2011338647A1/en not_active Abandoned
- 2011-12-06 CA CA2820586A patent/CA2820586A1/en not_active Abandoned
- 2011-12-06 KR KR1020137017362A patent/KR20130124518A/ko not_active Ceased
-
2013
- 2013-06-05 CL CL2013001602A patent/CL2013001602A1/es unknown
- 2013-06-10 ZA ZA2013/04237A patent/ZA201304237B/en unknown
-
2016
- 2016-12-26 JP JP2016251360A patent/JP2017095476A/ja active Pending
-
2017
- 2017-02-22 IL IL250726A patent/IL250726A0/en unknown
- 2017-03-28 AU AU2017202055A patent/AU2017202055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201509831XA (en) | 2015-12-30 |
| PH12013501193A1 (en) | 2013-07-15 |
| EP2648732A1 (en) | 2013-10-16 |
| CN103260624A (zh) | 2013-08-21 |
| BR112013014061A2 (pt) | 2016-09-13 |
| CL2013001602A1 (es) | 2013-10-25 |
| NZ611628A (en) | 2015-06-26 |
| CA2820586A1 (en) | 2012-06-14 |
| ZA201304237B (en) | 2014-08-27 |
| CN103260624B (zh) | 2015-06-03 |
| MX2013006464A (es) | 2013-07-29 |
| EA201390827A1 (ru) | 2013-12-30 |
| KR20130124518A (ko) | 2013-11-14 |
| EP2648732A4 (en) | 2014-04-30 |
| JP2013544887A (ja) | 2013-12-19 |
| US20120142730A1 (en) | 2012-06-07 |
| AU2017202055A1 (en) | 2017-04-20 |
| SG190449A1 (en) | 2013-07-31 |
| WO2012078591A8 (en) | 2012-08-02 |
| IL250726A0 (en) | 2017-04-30 |
| UA111959C2 (uk) | 2016-07-11 |
| WO2012078591A1 (en) | 2012-06-14 |
| JP2017095476A (ja) | 2017-06-01 |
| AU2011338647A8 (en) | 2013-09-05 |
| AU2011338647A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140872A1 (es) | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| RU2014109074A (ru) | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| NZ594056A (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| FI3439660T3 (fi) | Pimobendaanin käyttö sydämen koon pienentämiseen ja kliinisten oireiden alkamisen hidastamiseen potilaissa, joilla on hiippaläppäsairaudesta johtuva oireeton sydämen vajaatoiminta | |
| MX344303B (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| MX361741B (es) | Tratamientos médicos a base de anamorelina. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| NZ597675A (en) | Medicament for the long term nsaid use | |
| AR047154A1 (es) | Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| NZ599227A (en) | Therapeutic agent for chronic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |